Literature DB >> 27377700

Discrimination of Dysplastic Nevi from Common Melanocytic Nevi by Cellular and Molecular Criteria.

Hiroshi Mitsui1, Felix Kiecker2, Avner Shemer3, Maria Vittoria Cannizzaro4, Claire Q F Wang1, Nicholas Gulati1, Hanako Ohmatsu1, Kejal R Shah5, Patricia Gilleaudeau1, Mary Sullivan-Whalen1, Inna Cueto1, Neil Scott McNutt1, Mayte Suárez-Fariñas6, James G Krueger7.   

Abstract

Dysplastic nevi (DNs), also known as Clark's nevi or atypical moles, are distinguished from common melanocytic nevi by variegation in pigmentation and clinical appearance, as well as differences in tissue patterning. However, cellular and molecular differences between DNs and common melanocytic nevi are not completely understood. Using cDNA microarray, quantitative RT-PCR, and immunohistochemistry, we molecularly characterized DNs and analyzed the difference between DNs and common melanocytic nevi. A total of 111 probesets (91 annotated genes, fold change > 2.0 and false discovery rate < 0.25) were differentially expressed between the two lesions. An unexpected finding in DNs was altered differentiation and activation of epidermal keratinocytes with increased expression of hair follicle-related molecules (keratin 25, trichohyalin, ribonuclease, RNase A family, 7) and inflammation-related molecules (S100A7, S100A8) at both genomic and protein levels. The immune microenvironment of DNs was characterized by an increase of T helper type 1 (IFNγ) and T helper type 2 (IL13) cytokines as well as an upregulation of oncostatin M and CXCL1. DUSP3, which regulates cellular senescence, was identified as one of the disease discriminative genes between DNs and common melanocytic nevi by three independent statistical approaches and its altered expression was confirmed by immunohistochemistry. The molecular and cellular changes in which the epidermal-melanin unit undergoes follicular differentiation as well as upregulation of defined cytokines could drive complex immune, epidermal, and pigmentary alterations.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27377700     DOI: 10.1016/j.jid.2015.11.035

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Keratinocyte cadherin desmoglein 1 controls melanocyte behavior through paracrine signaling.

Authors:  Christopher R Arnette; Quinn R Roth-Carter; Jennifer L Koetsier; Joshua A Broussard; Hope E Burks; Kathleen Cheng; Christine Amadi; Pedram Gerami; Jodi L Johnson; Kathleen J Green
Journal:  Pigment Cell Melanoma Res       Date:  2019-10-10       Impact factor: 4.693

2.  Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.

Authors:  Bernice Y Yan; Sandra Garcet; Nicholas Gulati; Felix Kiecker; Judilyn Fuentes-Duculan; Patricia Gilleaudeau; Mary Sullivan-Whalen; Avner Shemer; Hiroshi Mitsui; James G Krueger
Journal:  Exp Dermatol       Date:  2018-12-21       Impact factor: 3.960

3.  A meta-analysis of transcriptome datasets characterizes malignant transformation from melanocytes and nevi to melanoma.

Authors:  Daniel Ortega-Bernal; Claudia H González-De La Rosa; Elena Arechaga-Ocampo; Miguel Angel Alvarez-Avitia; Nora Sobrevilla Moreno; Claudia Rangel-Escareño
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

4.  Aberrant Induction of a Mesenchymal/Stem Cell Program Engages Senescence in Normal Mammary Epithelial Cells.

Authors:  Benjamin L Bryson; Ilaria Tamagno; Sarah E Taylor; Neetha Parameswaran; Noah M Chernosky; Nikhila Balasubramaniam; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2020-12-22       Impact factor: 5.852

5.  NRF1 and NRF2 mRNA and Protein Expression Decrease Early during Melanoma Carcinogenesis: An Insight into Survival and MicroRNAs.

Authors:  Mari Hämäläinen; Hanna-Riikka Teppo; Sini Skarp; Kirsi-Maria Haapasaari; Katja Porvari; Katri Vuopala; Thomas Kietzmann; Peeter Karihtala
Journal:  Oxid Med Cell Longev       Date:  2019-09-04       Impact factor: 6.543

6.  Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma.

Authors:  Elizabeth S Borden; Anngela C Adams; Kenneth H Buetow; Melissa A Wilson; Julie E Bauman; Clara Curiel-Lewandrowski; H-H Sherry Chow; Bonnie J LaFleur; Karen Taraszka Hastings
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.575

Review 7.  Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression.

Authors:  Wei-Wen Sung; Chung-Hsing Chang
Journal:  Tzu Chi Med J       Date:  2021-07-16

8.  NRF3 Decreases during Melanoma Carcinogenesis and Is an Independent Prognostic Marker in Melanoma.

Authors:  Anni Immonen; Kirsi-Maria Haapasaari; Sini Skarp; Peeter Karihtala; Hanna-Riikka Teppo
Journal:  Oxid Med Cell Longev       Date:  2022-03-26       Impact factor: 6.543

Review 9.  Revisiting the roles of VHR/DUSP3 phosphatase in human diseases.

Authors:  Lilian Cristina Russo; Jéssica Oliveira Farias; Pault Yeison Minaya Ferruzo; Lucas Falcão Monteiro; Fábio Luís Forti
Journal:  Clinics (Sao Paulo)       Date:  2018-09-06       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.